JP2016538270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538270A5 JP2016538270A5 JP2016526213A JP2016526213A JP2016538270A5 JP 2016538270 A5 JP2016538270 A5 JP 2016538270A5 JP 2016526213 A JP2016526213 A JP 2016526213A JP 2016526213 A JP2016526213 A JP 2016526213A JP 2016538270 A5 JP2016538270 A5 JP 2016538270A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cgvhd
- day
- administered
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 35
- 230000000153 supplemental effect Effects 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895981P | 2013-10-25 | 2013-10-25 | |
| US61/895,981 | 2013-10-25 | ||
| US201361910945P | 2013-12-02 | 2013-12-02 | |
| US61/910,945 | 2013-12-02 | ||
| US201461973176P | 2014-03-31 | 2014-03-31 | |
| US201461973173P | 2014-03-31 | 2014-03-31 | |
| US61/973,176 | 2014-03-31 | ||
| US61/973,173 | 2014-03-31 | ||
| PCT/US2014/062277 WO2015061751A1 (en) | 2013-10-25 | 2014-10-24 | Methods of treating and preventing graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083275A Division JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538270A JP2016538270A (ja) | 2016-12-08 |
| JP2016538270A5 true JP2016538270A5 (OSRAM) | 2017-11-30 |
Family
ID=52993667
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526213A Ceased JP2016538270A (ja) | 2013-10-25 | 2014-10-24 | 移植片対宿主病を処置し予防する方法 |
| JP2019083275A Active JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
| JP2020091997A Active JP6869400B2 (ja) | 2013-10-25 | 2020-05-27 | 移植片対宿主病を処置し予防する方法 |
| JP2021067193A Active JP7090396B2 (ja) | 2013-10-25 | 2021-04-12 | 移植片対宿主病を処置し予防する方法 |
| JP2022095164A Active JP7465305B2 (ja) | 2013-10-25 | 2022-06-13 | 移植片対宿主病を処置し予防する方法 |
| JP2024054467A Pending JP2024099527A (ja) | 2013-10-25 | 2024-03-28 | 移植片対宿主病を処置し予防する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083275A Active JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
| JP2020091997A Active JP6869400B2 (ja) | 2013-10-25 | 2020-05-27 | 移植片対宿主病を処置し予防する方法 |
| JP2021067193A Active JP7090396B2 (ja) | 2013-10-25 | 2021-04-12 | 移植片対宿主病を処置し予防する方法 |
| JP2022095164A Active JP7465305B2 (ja) | 2013-10-25 | 2022-06-13 | 移植片対宿主病を処置し予防する方法 |
| JP2024054467A Pending JP2024099527A (ja) | 2013-10-25 | 2024-03-28 | 移植片対宿主病を処置し予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US9795604B2 (OSRAM) |
| EP (2) | EP4115886A1 (OSRAM) |
| JP (6) | JP2016538270A (OSRAM) |
| KR (5) | KR102671643B1 (OSRAM) |
| CN (2) | CN111265531B (OSRAM) |
| AU (5) | AU2014339815B2 (OSRAM) |
| CA (2) | CA3103411A1 (OSRAM) |
| EA (1) | EA201690745A1 (OSRAM) |
| IL (2) | IL245183B (OSRAM) |
| MX (2) | MX392373B (OSRAM) |
| PH (2) | PH12016500768A1 (OSRAM) |
| TW (1) | TWI620565B (OSRAM) |
| WO (1) | WO2015061751A1 (OSRAM) |
| ZA (1) | ZA202208792B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
| US9296753B2 (en) | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
| EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| AU2014339815B2 (en) | 2013-10-25 | 2020-03-26 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| TWI743019B (zh) * | 2013-12-02 | 2021-10-21 | 美商製藥公司 | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| US10793566B2 (en) | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| MX384833B (es) | 2016-01-21 | 2025-03-14 | Zibo Biopolar Changsheng Pharmaceutical Co Ltd | Inhibidores de tirosina quinasa de bruton |
| EP3426637B1 (en) | 2016-03-11 | 2022-02-09 | Angel Pharmaceutical Co., Ltd. | Compounds and methods for modulating bruton's tyrosine kinase |
| US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
| CN110621321B (zh) | 2017-03-15 | 2024-06-21 | 浩康生物系统公司 | 用于造血干细胞移植的组合物和方法 |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| US20220354629A1 (en) * | 2018-01-09 | 2022-11-10 | E2Bio Life Sciences, Llc | Method and device for the enhancement of topical treatments for oral mucositis and other oral conditions |
| CN109481666B (zh) * | 2018-12-21 | 2020-11-03 | 江苏省中医院 | 一种人体血液肿瘤pdx模型的建立方法 |
| CN112439069A (zh) * | 2019-08-28 | 2021-03-05 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂在制备治疗移植物抗宿主病的药物中的用途 |
| US12496303B2 (en) | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
| US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| BR0014073A (pt) | 1999-09-17 | 2002-07-16 | Abbott Gmbh & Co Kg | Pirazolopirimidinas como agentes terapêuticos |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| EP1222187B1 (en) | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| AU4508601A (en) | 1999-11-30 | 2001-06-18 | Parker Hughes Institute | Inhibitors of collagen-induced platelet aggregation |
| IL150059A0 (en) | 1999-12-17 | 2002-12-01 | Ariad Pharma Inc | Novel heterocycles |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| US20030040461A1 (en) | 2000-10-23 | 2003-02-27 | Mcatee C. Patrick | Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states |
| JP2004514732A (ja) | 2000-12-06 | 2004-05-20 | ファルマシア・コーポレーション | 迅速に分散する医薬組成物 |
| DE60117605T2 (de) | 2000-12-21 | 2006-12-07 | Bristol-Myers Squibb Co. | Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES |
| US20030118078A1 (en) | 2001-08-10 | 2003-06-26 | Carlson Eric D. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
| US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
| SE0202461D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| NZ545421A (en) | 2003-09-08 | 2010-03-26 | Aventis Pharma Inc | Thienopyrazoles |
| US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| CN1934113B (zh) | 2004-01-26 | 2011-11-09 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的组合物 |
| US20050209284A1 (en) | 2004-02-12 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tec kinase inhibitors |
| WO2006036941A2 (en) | 2004-09-27 | 2006-04-06 | Kosan Biosciences Incorporated | Specific kinase inhibitors |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
| WO2007016977A1 (de) | 2005-08-05 | 2007-02-15 | Delica Ag | Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel |
| ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
| WO2007058832A2 (en) | 2005-11-12 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors |
| US20080293714A1 (en) | 2005-12-20 | 2008-11-27 | Joerg Martin Bentzien | Tec Kinase Inhibitors |
| RU2008133161A (ru) * | 2006-01-13 | 2010-02-20 | Фармасайкликс, Инк. (Us) | Ингибиторы тирозин киназ и их применение |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US8987233B2 (en) | 2006-11-03 | 2015-03-24 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| CA3001152A1 (en) * | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| TWI475996B (zh) | 2007-10-19 | 2015-03-11 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2011017219A1 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Imidazoquinoxalinones and anti-tumor treatment |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
| US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
| JP2014520115A (ja) | 2011-06-09 | 2014-08-21 | ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド | 移植片対宿主病を治療または予防する方法 |
| EP2726077A4 (en) * | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION |
| CN110801454A (zh) * | 2011-10-19 | 2020-02-18 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
| WO2013085893A1 (en) * | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| EP2836214B1 (en) * | 2012-04-11 | 2018-06-27 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| DK2854850T3 (da) | 2012-05-25 | 2021-08-30 | Sloan Kettering Inst Cancer Res | Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom |
| US9296753B2 (en) | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| US9658228B2 (en) * | 2013-01-30 | 2017-05-23 | The Board of Trustees of the Leland University Junior University | Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients |
| WO2014127200A1 (en) * | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| JP2016512549A (ja) * | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| US20160287592A1 (en) * | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
| AU2014339815B2 (en) * | 2013-10-25 | 2020-03-26 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| TWI743019B (zh) * | 2013-12-02 | 2021-10-21 | 美商製藥公司 | 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法 |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
-
2014
- 2014-10-24 AU AU2014339815A patent/AU2014339815B2/en active Active
- 2014-10-24 KR KR1020227034478A patent/KR102671643B1/ko active Active
- 2014-10-24 CN CN202010072071.8A patent/CN111265531B/zh active Active
- 2014-10-24 EA EA201690745A patent/EA201690745A1/ru unknown
- 2014-10-24 MX MX2021009400A patent/MX392373B/es unknown
- 2014-10-24 TW TW103136912A patent/TWI620565B/zh active
- 2014-10-24 CN CN201480068676.2A patent/CN106102745B/zh active Active
- 2014-10-24 CA CA3103411A patent/CA3103411A1/en active Pending
- 2014-10-24 KR KR1020257036179A patent/KR20250162912A/ko active Pending
- 2014-10-24 US US14/523,650 patent/US9795604B2/en active Active
- 2014-10-24 JP JP2016526213A patent/JP2016538270A/ja not_active Ceased
- 2014-10-24 EP EP22179611.3A patent/EP4115886A1/en active Pending
- 2014-10-24 KR KR1020167013594A patent/KR102357526B1/ko active Active
- 2014-10-24 KR KR1020237041412A patent/KR20230170797A/ko active Pending
- 2014-10-24 KR KR1020227002810A patent/KR102452866B1/ko active Active
- 2014-10-24 MX MX2016005294A patent/MX385122B/es unknown
- 2014-10-24 CA CA2928721A patent/CA2928721C/en active Active
- 2014-10-24 EP EP14856623.5A patent/EP3060218A4/en not_active Withdrawn
- 2014-10-24 WO PCT/US2014/062277 patent/WO2015061751A1/en not_active Ceased
-
2016
- 2016-04-18 IL IL245183A patent/IL245183B/en unknown
- 2016-04-25 PH PH12016500768A patent/PH12016500768A1/en unknown
-
2017
- 2017-05-03 US US15/586,058 patent/US10463668B2/en active Active
-
2019
- 2019-04-24 JP JP2019083275A patent/JP6712427B2/ja active Active
- 2019-09-25 US US16/582,945 patent/US10695350B2/en active Active
-
2020
- 2020-05-27 JP JP2020091997A patent/JP6869400B2/ja active Active
- 2020-06-12 US US16/900,624 patent/US20210121463A1/en not_active Abandoned
- 2020-06-26 AU AU2020204270A patent/AU2020204270A1/en not_active Abandoned
-
2021
- 2021-01-08 PH PH12021550052A patent/PH12021550052A1/en unknown
- 2021-04-12 JP JP2021067193A patent/JP7090396B2/ja active Active
- 2021-08-24 IL IL285843A patent/IL285843A/en unknown
-
2022
- 2022-04-22 AU AU2022202686A patent/AU2022202686B2/en active Active
- 2022-04-27 US US17/730,764 patent/US20230097340A1/en not_active Abandoned
- 2022-06-13 JP JP2022095164A patent/JP7465305B2/ja active Active
- 2022-08-05 ZA ZA2022/08792A patent/ZA202208792B/en unknown
-
2023
- 2023-09-25 US US18/372,398 patent/US20240293408A1/en not_active Abandoned
- 2023-11-30 AU AU2023274176A patent/AU2023274176B2/en active Active
-
2024
- 2024-03-28 JP JP2024054467A patent/JP2024099527A/ja active Pending
- 2024-12-19 US US18/987,370 patent/US20250345335A1/en active Pending
-
2025
- 2025-11-10 AU AU2025263907A patent/AU2025263907A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538270A5 (OSRAM) | ||
| JP2017501848A5 (OSRAM) | ||
| JP2014506321A5 (OSRAM) | ||
| JP2016518337A5 (OSRAM) | ||
| JP2015157821A5 (OSRAM) | ||
| JP2017075173A5 (OSRAM) | ||
| JP2013147511A5 (OSRAM) | ||
| JP2015516456A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2019530713A5 (OSRAM) | ||
| JP2016512817A5 (OSRAM) | ||
| JP2020513032A5 (OSRAM) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2016537338A5 (OSRAM) | ||
| JP2014210824A5 (OSRAM) | ||
| JP2015522603A5 (OSRAM) | ||
| JP2017529355A5 (OSRAM) | ||
| JP2016531853A5 (OSRAM) | ||
| JP2019528290A5 (OSRAM) | ||
| Zhang et al. | Fecal Microbiota Transplantation Modulates Th17/Treg Balance via JAK/STAT Pathway in ARDS Rats | |
| JP2017511372A5 (OSRAM) | ||
| JP2008525317A5 (OSRAM) | ||
| JP2016514142A5 (OSRAM) | ||
| JP2012516899A5 (OSRAM) | ||
| Khalid | Serositis, pleural effusion and severe pulmonary arterial hypertension: case report |